Cullinan Therapeutics, Inc. Common Stock

CGEM trades at its 52-week high with a microscopic $0.9B market cap and an RSI of 62.5, suggesting momentum but creeping toward overbought territory. The 20.04% short interest—roughly one-fifth of the float—creates meaningful squeeze risk if positive catalysts emerge. With no earnings (P/E n/a), this is a pure clinical-stage biotech bet where technicals matter more than fundamentals. The confluence of elevated valuation, stretched positioning, and short exposure means any news could trigger violent repricing in either direction. The setup screams speculative tension rather than fundamental stability.